阴道黄体酮预防声像图显示宫颈短的妇女自发早产：PREGNANT 试验的故事。

IF 1.4 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Clinical obstetrics and gynecology Pub Date : 2024-04-05 DOI:10.1097/grf.0000000000000867

Roberto Romero, Arun Meyyazhagan, Sonia S Hassan, George W Creasy, Agustin Conde-Agudelo

{"title":"阴道黄体酮预防声像图显示宫颈短的妇女自发早产：PREGNANT 试验的故事。","authors":"Roberto Romero, Arun Meyyazhagan, Sonia S Hassan, George W Creasy, Agustin Conde-Agudelo","doi":"10.1097/grf.0000000000000867","DOIUrl":null,"url":null,"abstract":"The PREGNANT trial was a randomized, placebo-controlled, multicenter trial designed to determine the efficacy and safety of vaginal progesterone (VP) to reduce the risk of birth <33 weeks and of neonatal complications in women with a sonographic short cervix (10 to 20 mm) in the mid-trimester (19 to 23 6/7 wk). Patients allocated to receive VP had a 45% lower rate of preterm birth (8.9% vs 16.1%; relative risk = 0.55; 95% CI: 0.33-0.92). Neonates born to mothers allocated to VP had a 60% reduction in the rate of respiratory distress syndrome. This article reviews the background, design, execution, interpretation, and impact of the PREGNANT Trial.","PeriodicalId":10415,"journal":{"name":"Clinical obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vaginal Progesterone to Prevent Spontaneous Preterm Birth in Women With a Sonographic Short Cervix: The Story of the PREGNANT Trial.\",\"authors\":\"Roberto Romero, Arun Meyyazhagan, Sonia S Hassan, George W Creasy, Agustin Conde-Agudelo\",\"doi\":\"10.1097/grf.0000000000000867\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The PREGNANT trial was a randomized, placebo-controlled, multicenter trial designed to determine the efficacy and safety of vaginal progesterone (VP) to reduce the risk of birth <33 weeks and of neonatal complications in women with a sonographic short cervix (10 to 20 mm) in the mid-trimester (19 to 23 6/7 wk). Patients allocated to receive VP had a 45% lower rate of preterm birth (8.9% vs 16.1%; relative risk = 0.55; 95% CI: 0.33-0.92). Neonates born to mothers allocated to VP had a 60% reduction in the rate of respiratory distress syndrome. This article reviews the background, design, execution, interpretation, and impact of the PREGNANT Trial.\",\"PeriodicalId\":10415,\"journal\":{\"name\":\"Clinical obstetrics and gynecology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical obstetrics and gynecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/grf.0000000000000867\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical obstetrics and gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/grf.0000000000000867","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

PREGNANT 试验是一项随机、安慰剂对照、多中心试验，旨在确定阴道黄体酮 (VP) 的有效性和安全性，以降低妊娠中期（19 至 23 6/7 周）声像图显示宫颈短（10 至 20 毫米）的妇女的早产风险和新生儿并发症风险。接受 VP 治疗的患者早产率降低了 45%（8.9% vs 16.1%；相对风险 = 0.55；95% CI：0.33-0.92）。接受 VP 治疗的母亲所生的新生儿患呼吸窘迫综合征的比例降低了 60%。本文回顾了 PREGNANT 试验的背景、设计、执行、解释和影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Vaginal Progesterone to Prevent Spontaneous Preterm Birth in Women With a Sonographic Short Cervix: The Story of the PREGNANT Trial.

The PREGNANT trial was a randomized, placebo-controlled, multicenter trial designed to determine the efficacy and safety of vaginal progesterone (VP) to reduce the risk of birth <33 weeks and of neonatal complications in women with a sonographic short cervix (10 to 20 mm) in the mid-trimester (19 to 23 6/7 wk). Patients allocated to receive VP had a 45% lower rate of preterm birth (8.9% vs 16.1%; relative risk = 0.55; 95% CI: 0.33-0.92). Neonates born to mothers allocated to VP had a 60% reduction in the rate of respiratory distress syndrome. This article reviews the background, design, execution, interpretation, and impact of the PREGNANT Trial.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical obstetrics and gynecology 医学-妇产科学

CiteScore

2.70

自引率

0.00%

发文量

186

审稿时长

3 months

期刊介绍： Each issue of Clinical Obstetrics and Gynecology is a complete symposium on one or two timely topics of interest in obstetrics and gynecology. For each quarterly issue, two prominent guest editors solicit contributions on key clinical topics of interest to practicing physicians. Procedures, current clinical problems, medical and surgical treatments, and effective diagnostic aids are all carefully reviewed in original articles. The result is an instructive resource that dispenses trustworthy clinical guidance that enhances your understanding of key areas of your practice.